The Pharma Data
DECEMBER 13, 2020
.–( BUSINESS WIRE )– EdiGene, Inc. which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, today announced the appointment of Bo Zhang, Ph.D., as Head of Business Development. Both will report to Dr. Dong Wei, CEO of EdiGene.
The Pharma Data
JUNE 7, 2023
a biotechnology company specializing in the development of lipid nanoparticle (LNP) delivery systems for molecular therapeutics. Acuitas’ LNP technology will support Bayer’s in vivo gene editing and protein replacement programs by specifically delivering RNA payloads to the desired target organ, the liver.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
JUNE 16, 2023
Our partners are leading companies (Conveyxo, Exo Biologics, Livedrop, Genflow Biosciences, Orgenesis, Theracell Advanced Biotechnology, Cylix Group) for each step of the production of ATMPs, which will then be developed and clinically evaluated by BioSenic. The ISCT 2023 Annual Meeting took place in Paris, France from May 31 to June 3 2023.
Drug Discovery World
JUNE 14, 2023
On this topic, Becky Cap, SVP, Business Development, Advanced Therapies at BioBridge Global, notes that embassies have struggled in the development and regulatory space to find a home. The ISCT 2023 Annual Meeting took place in Paris, France from May 31 to June 3 2023. First, the importance of cell collections.
The Pharma Data
JANUARY 12, 2021
Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist with global Biotech and Pharma R&D experience in Phase I-IV therapeutics as well as in-vivo & in-vitro diagnostics, across many modalities. He has in depth Global Development Expertise (e.g. Dr. Graham earned an M.D.,
The Pharma Data
JANUARY 4, 2021
Kiromic chPD1 has shown in preclinical data to show a cytotoxic response in 9 different in vivo models with 100% long-term PFS with the induction of host memory responses. PD-1 has always been a challenge for CAR-T development. “We believe Prof. About PD-1 Check-point inhibition. Dr. Barber is a tumor immunologist.
Drug Discovery World
NOVEMBER 9, 2023
The first three include: Sungjin Park, PhD, CEO, Onegene Biotechnology, on: ‘UniStac: Enzyme-mediated conjugation technology for accelerated development of tetraspecific NASH drug’. Croasdale-Wood will then participate in a keynote chat, interviewed by Miho.
Expert insights. Personalized for you.
40 
Let's personalize your content